ArticleESMO open2026
Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B-cell malignancies.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn patients with B-cell malignancies, treatment with the first-generation Bruton tyrosine kinase (BTK) inhibitor ibrutinib can be limited by toxicities resulting from off-target binding. Zanubrutinib, a next-generation BTK inhibitor, was designed to maximize BTK occupancy and minimize off-target effects. MATERIALS AND
methodsA post hoc safety analysis was carried out with pooled data from Asian patients with B-cell malignancies who received zanubrutinib in eight clinical trials, including ALPINE, which compared zanubrutinib with ibrutinib. Rates and severity of treatment-emergent adverse events (TEAEs), overall exposure-adjusted incidence rates (EAIRs) of AEs of special interest (AESIs; defined as pooled terms), and EAIRs of AESIs over time were assessed.
resultsThe analyses included 406 Asian patients with a median treatment duration of 25.0 months; 38.7% of patients received treatment for ≥36 months. Upper respiratory tract infection (38.2%), pneumonia (26.4%), rash (21.2%), and diarrhea (16.5%) were the most common nonhematologic TEAEs. The most common nonhematologic grade ≥3 TEAEs were pneumonia (16.0%) and upper respiratory tract infection (6.9%). Serious TEAEs occurred in 43.8% of patients; pneumonia (14.5%) was the only event occurring in >10% of patients. TEAEs led to treatment discontinuation in 10.6% of patients and death in 4.9%, mostly due to infections. EAIRs for atrial fibrillation/flutter and hypertension were 0.02 and 0.56 persons per 100 person-months, respectively. In the comparative analysis, most EAIRs of AESIs were numerically lower in patients treated with zanubrutinib versus ibrutinib. Over time, EAIRs of AESIs remained relatively constant or decreased in the pooled Asian population and were similar to or lower than those with ibrutinib for up to 36 months.
conclusionsZanubrutinib was well tolerated in Asian patients with B-cell malignancies. The safety profile in this population was consistent with that in previous global study populations. These findings suggest that long-term zanubrutinib treatment is an appropriate option for Asian patients with B-cell malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.